Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical, Inc. develops precision nerve-targeted medical device technology for diagnosing and treating diseases involving the nervous system. The company’s platform includes a catheter-based microchip sensing array intended to detect and differentiate neural signals and support transvascular approaches to peripheral nerve identification and treatment.
Recurring AMIX news centers on clinical and scientific updates for transvascular radiofrequency energy-based ablation, including pain mitigation research in pancreatic adenocarcinoma and peripheral nerve modulation. Company announcements also cover medical and interventional conference presentations, abstract selections, publication strategy, corporate presentations, and the clinical validation process for its minimally invasive nerve-targeted platform.
Autonomix Medical (NASDAQ: AMIX) announced acceptance of long-term clinical data titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation” for presentation at Digestive Disease Week 2026 (May 2–5, 2026) in Chicago and virtually.
The abstract covers long-term outcomes for a transvascular radiofrequency nerve‑targeted ablation approach intended to reduce severe pain in pancreatic adenocarcinoma patients.
Autonomix Medical (NASDAQ: AMIX) will present new long-term clinical data on a transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma at ECIO 2026 in Basel, April 26–30, 2026.
The oral presentation (Abstract No. 350) titled “Pain mitigation in pancreatic adenocarcinoma: a long-term analysis of denervation via transvascular RF energy-based ablation” will be delivered by Nikola Cesarovic, PhD, on April 29, 2026, 8:30–10:00 AM (Europe/Zurich), highlighting long-term outcomes from the company’s ongoing clinical evaluation of its minimally invasive, transvascular RF energy-based approach.
Autonomix Medical (NASDAQ: AMIX) announced its abstract, “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation,” was selected as a Featured Abstract for podium presentation at SIR 2026 in Toronto. The presentation is scheduled for April 12, 2026, 4:03–4:12 PM and will be delivered by Dr. Lindsay Machan. The study reports long-term evaluation of transvascular radiofrequency denervation for sustained pain mitigation in pancreatic adenocarcinoma and will be highlighted in the JVIR 2026 Annual Scientific Meeting Supplement.
Autonomix Medical (NASDAQ: AMIX) announced that Brad Hauser, President and CEO, will present at LSI USA ’26 on March 17, 2026 at 9:15 AM PT. Management will be available for in-person one-on-one meetings with registered, qualified investors attending the conference.
The presentation is accessible to registered attendees only. LSI USA '26 is a global medtech summit for executives, investors and innovators featuring keynote sessions, panels and startup presentations.
Autonomix Medical (NASDAQ: AMIX) was selected for an oral presentation in the CRT 2026 Best Innovation Competition for its talk “Illuminating The Nervous System With Transvascular Precision-guided Technology.”
CEO Brad Hauser will present on March 9, 2026, 4:19–4:27 PM ET in the International Ballroom – West, highlighting the company’s transvascular, nerve-targeted technology and its clinical relevance.
Autonomix Medical (NASDAQ: AMIX) announced a Top Abstract selection at CRT 2026 for a podium presentation on March 7, 2026. The presentation will cover clinical feasibility and early outcomes for a novel transvascular RF peripheral nerve neurolysis technique that targets nerve signals for precision modulation.
The six-minute podium will appear in the Hypertension Therapies and Renal Denervation session, highlighting early clinical data and potential applicability across multiple peripheral nerve indications.
Autonomix Medical (NASDAQ: AMIX) released a new CEO Corner segment on Feb 25, 2026 featuring President and CEO Brad Hauser discussing the company’s publication strategy and efforts to expand scientific publications and presentations over the past 12–18 months.
Hauser emphasizes submitting clinical and technical data to competitive, peer-reviewed forums to validate Autonomix’s technology, build clinical credibility, and support long-term growth; the segment is available on the CEO Corner of the company website and social channels.
Autonomix Medical (NASDAQ: AMIX) announced that Clarke Wilkirson, PhD, will present new long-term clinical data on pain mitigation in pancreatic adenocarcinoma at the SSO 2026 Annual Meeting March 5-7 in Phoenix.
The oral podium presentation describes a long-term analysis of denervation using a minimally invasive transvascular RF energy-based ablation and its potential effects on pain control and quality of life.
Autonomix Medical (NASDAQ: AMIX) will present final clinical data on a transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma at the SIO 2026 Annual Scientific Meeting in Savannah, GA (Feb 4-8, 2026).
The ePoster (Abstract #327) will be presented by Clarke Wilkirson, PhD on Feb 6, 2026, 5:30–6:30 PM EST, including a 10-minute talk and 5-minute discussion during the Science and Sips reception.
Autonomix (NASDAQ: AMIX) presented post hoc subgroup data from its Proof-of-Concept 1 study at the 2026 ASCO GI symposium showing rapid, durable pain relief for pancreatic cancer patients across Stage 2–4 disease.
Key findings: responding patients showed marked pain reduction within 24 hours; at 7 days, 93.75% (N=16) improved from severe to mild/moderate pain; at 4–6 weeks about two-thirds (N=9) maintained mild/elimination pain; at 3 months no responding patients (N=6) reported severe pain and 50% maintained mild/elimination levels. The analysis included three patients with unknown stage and noted limited longer-term follow-up in some due to disease progression.